Noninferiority was not demonstrated between speedy and staged full revascularisation in sufferers with ST-segment elevation myocardial infarction (STEMI) and multivessel illness present process percutaneous coronary intervention (PCI), based on late-breaking analysis introduced in a Sizzling Line session immediately at ESC Congress 20251.
Multivessel coronary artery illness – when at the least two coronary arteries are blocked – impacts nearly half of sufferers who’ve STEMI, a sort of coronary heart assault. ESC Pointers advocate full revascularisation with PCI in sufferers with STEMI and multivessel illness, involving treating the blocked artery that prompted the center assault (offender lesion) plus different affected vessels (non-culprit lesions).2
Explaining the purpose of the OPTION-STEMI trial, its Principal Investigator, Professor Youngkeun Ahn from Chonnam Nationwide College Hospital, Gwangju, South Korea, acknowledged, “We in contrast speedy full revascularisation with PCI for the offender and non-culprit lesions throughout the identical process with staged full revascularisation, the place PCI for non-culprit lesions came about on one other day throughout the identical hospitalisation. We included a broad inhabitants of sufferers with STEMI and multivessel coronary artery illness.”
The OPTION-STEMI trial was an investigator-initiated, open-label, noninferiority randomised trial carried out in 14 websites in South Korea. Sufferers have been eligible in the event that they introduced with STEMI and multivessel coronary artery illness and underwent profitable PCI for a offender artery.
Sufferers have been randomised 1:1 to both speedy full revascularisation with simultaneous PCI for the offender and non-culprit lesions or staged full revascularisation that included PCI for non-culprit lesions on one other day in the course of the index hospitalisation. The first endpoint was the composite of all-cause demise, non-fatal MI and any unplanned revascularisation at 1 yr.
A complete of 994 sufferers underwent randomisation. Median age was 66 years and 79% of sufferers have been males. One-third (33%) of sufferers introduced with Killip class II or III, indicating indicators of coronary heart failure. The median size of hospital keep was 4 days within the speedy group and 5 days within the staged group. Within the staged group, the median time to the second process was 3 days.
At 1 yr, the first endpoint of demise, MI and any unplanned revascularisation occurred in 13.1% of sufferers within the speedy group and 10.8% within the staged group (hazard ratio (HR) 1.24; 95% confidence interval (CI) 0.86 to 1.79; p for noninferiority=0.24), with noninferiority not established.
Prespecified subgroup analyses steered heterogeneity within the therapy impact based on the Killip class. Fast full revascularisation was related to extra hurt in sufferers with indicators of coronary heart failure (Killip class ≥II: HR 1.79; 95% CI 1.05 to three.05) than in sufferers with out coronary heart failure indicators (Killip class I: HR 0.84; 95% CI 0.50 to 1.41; p for interplay=0.04).
Relating to secondary endpoints, non-fatal MI occurred in 3.9% of the sufferers within the speedy group and 5.1% within the staged group (HR 0.77; 95% CI 0.42 to 1.39), whereas demise occurred in 7.5% vs. 5.3% of sufferers, respectively (HR 1.44; 95% CI 0.87 to 2.38).
Within the OPTION-STEMI trial, speedy full revascularisation was not noninferior to staged full revascularisation throughout index hospitalisation, that means we don’t have conclusive proof that speedy is much like staged full revascularisation.”
Youngkeun Ahn, Examine Principal Investigator and Professor, Chonnam Nationwide College Hospital
Ahn added, “Two current trials have proven that speedy full revascularisation was noninferior to staged full revascularisation; nonetheless, one trial enrolled STEMI or non-ST-elevation acute coronary syndrome sufferers, whereas the opposite enrolled STEMI sufferers at low scientific threat.”
“In each, the staged process was carried out weeks after the preliminary process. Given our findings in sufferers with indicators of coronary heart failure, it appears prudent to restrict speedy full revascularisation to secure STEMI sufferers with multivessel illness at low scientific threat,” Ahn concluded.
Supply:
European Society of Cardiology
